The CANTOS trial provided the first clinical evidence that anti-inflammatory therapy can reduce cardiovascular risk: In 10,061 post-myocardial infarction patients with elevated high-sensitivity C-reactive protein, the IL-1β monoclonal antibody canakinumab significantly reduced inflammatory markers (26%–41% greater hs-CRP reduction vs. placebo) without affecting lipid levels. Here, IL1B is linked to myocardial infarction.